Icodextrine peritoneal dialysis solution in clinical practice;Icodextrinový peritoneální dialyzační roztok v klinické praxi

Vnitrni Lekarstvi

Volumn 54, Issue 12, 2008, Pages 1155-1160

  Opatrná, Sylvie ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Icodextrin; Peritoneal dialysis; Peritoneal dialysis fluid; Ultrafiltration

Indexed keywords

GLUCOSE; GLUCOSE POLYMER; ICODEXTRIN; ISOTOPE; PEPTIDOGLYCAN;

BACTERIAL CELL WALL; BACTERIAL PERITONITIS; BACTERIUM CONTAMINATION; BLOOD PRESSURE REGULATION; CLINICAL PRACTICE; COLLOID; DIABETIC PATIENT; DIALYSATE; DIALYSIS MEMBRANE; GLYCEMIC CONTROL; HEART LEFT VENTRICLE MASS; HEART VENTRICLE; HEMODIALYSIS PATIENT; HEMODYNAMICS; HUMAN; HYDRATION; HYPERINSULINEMIA; HYPERLEPTINEMIA; HYPERLIPIDEMIA; INCIDENCE; LONG TERM CARE; MEMBRANE PERMEABILITY; MORTALITY; OSMOSIS; PERITONEAL DIALYSIS; PERITONEUM; PRESCRIPTION; REVIEW; SYSTEMIC CIRCULATION; ULTRAFILTRATION;

GLUCANS; GLUCOSE; HEMODIALYSIS SOLUTIONS; HEMODYNAMICS; HUMANS; PERITONEAL DIALYSIS; PERITONEUM; PERITONITIS; ULTRAFILTRATION; WATER-ELECTROLYTE BALANCE;

EID: 57749178234     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Hain H, Kessel M. Aspects of new solutions for peritoneal dialysis. Nephrol Dial Transplant 1987; 2: 67-72.
2. Kopple JD, Bernard D, Messana J et al. Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int 1995; 47: 1148-1157.
3. Mistry CD, Gokal R, Peers E et al. A randomized multicenter clinical trial comparing isosmolar Icodextrin with hyperosmolar glucose solutions in CAPD. Kidney Int 1994;46:496-503.
4. Finkelstein F, Healy H, Abu-Alfa A et al. Superiority of Icodextrin Compared with 4.25% Dextrose for Peritoneal Ultrafiltration. J Am Soc Nephrol 2005; 16: 546-554.
5. Araújo MRT, Pecoits-Filho RFS, Junior JER et al. The relationship between ultrafiltrate volume with icodextrin and peritoneal transport pattern according to the peritoneal equilibration test. Perit Dial Int 2002; 22: 229-233.
6. Wolfson M, Piraino B, Hamburger R et al. A Randomized Controlled Trial to Evaluate the Efficacy and Safety of Icodextrin in Peritoneal Dialysis. Am J Kidney Dis 2002; 5: 1055-1065.
7. Mujais S. Microbiology and outcome of peritonitis in North America. Kidney Int Suppl 2006; 103: S55-S62.
8. Dombros N, Dratwa M, Feriani M et al. European best practice guidelines for peritoneal dialysis. 3 Peritoneal access. Nephrol Dial Transplant 2005; 20 (Suppl 9): ix8-ix12.
9. Opatrná S. Can be incidence of peritonitis associated with peritoneal dialysis further decreased? Vnitř Lék 2004; 50: 578-581.
10. Hájková B, Fixa P. The latest trends in the treatment peritonitis of the patients on peritoneal dialysis. Vnitř Lék 2004; 50: 619-623.
11. Opatrná S, Klaboch J. Specific aspects of peritoneal dialysis in diabetic patients. Vnitř Lék 2008; 54: 523-529.
12. Posthuma N, ter Wee PM, Verbrugh HA et al. Icodextrin use in CCPD patients during peritonitis: ultrafiltration and serum disaccharide concentrations. Nephrol Dial Transplant 1998; 13: 2341-2344.
13. Konings CJAM, KoomanJP, Schonck M et al. Fluid status, blood pressure, and cardiovascular abnormalities in patients on peritoneal dialysis. Perit Dial Int 2002; 22: 477-487.
14. Woodrow G, Stables G, Oldroyd B et al. Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis. Nephrol Dial Transplant 1999; 14: 1530-1535.
15. Davies SJ, Woodrow G, Donovan K et al. Icodextrin Improves the Fluid Status of Peritoneal Dialysis Patients: Results of a Double-Blind Randomized Controlled Trial. J Am Soc Nephrol 2003; 14: 2338-2344.
16. Konings CJAM, KoomanJP, Schonck M et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: A randomized study. Kidney Int 2003; 63: 1556-1563.
17. Selby NM, Fonseca S, Hulme L et al. hypertonicglucose-based peritoneal dialysate is associated with higher blood pressure and adverse hemodynamics as compared with icodextrin. Nephrol Dial Transplant 2005; 20: 1848-1853.
18. Woods HF. Icodextrin and haemodynamics. Nephrol Dial Transplant 2006; 21: 820.
19. Marshall J, Jennings P, Scott A et al. Glycemic control in diabetic CAPD patients assessed by continusou glucose monitoring system (CGMS). Kidney Int 2003; 64: 1480-1486.
20. Babazono T, Nakamoto H, Kasai K et al. Effects of Icodextrin on Glycemic and Lipid Profiles in Diabetic Patients Undergoing Peritoneal Dialysis. Am J Nephrol 2007;27:409-415.
21. Gursu EM, Ozdemir A, Yalinbas B et al. The effect of icodextrin and glucose-containing solutions on insulin resistance in CAPD patients. Clin Nephrol 2006; 66: 263-268.
22. Canbakan M, Sahin GM. Icodextrine and Insulin Resistance in Continuous Ambulatory Peritoneal Dialysis Patients. Ren Fail 2007; 29: 289-293
23. Amici G, Orrasch M, da Rin GD et al. Hyperinsulinism Reduction Associated with Icodextrin Treatment in Continuous Ambulatory Peritoneal Dialysis Patients. Adv Perit Dial 2001; 17: 80-83.
24. Opatrná S, Racek J, Stehlík P et al. Effect of a dialysis solution with icodextrin on ultrafiltration and selected metabolic parameters in patients treated with peritoneal dialysis. Čas Lék Čes 2002; 141: 281-285.
25. Kanbay M, Bavbed N, Delibasi T et al. Effect of Peritoneal Dialysis Solution Type on Serum Lipid Levels in End-Stage Renal Disease. Ren Fail 2007; 29: 309-313.
26. Martikainen T, Teppo AM, Gronhagen-Riska C et al. Benefit of glucose-free dialysis solutions on glucose and lipid metabolism in peritoneal dialysis patients. Blood Purif 2005; 23: 303-310.
27. Bredie SJ, Bosch FH, Demacker PN et al. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial lnt 2001; 21: 275-281.
28. Hithaishi C, Lobbedez T, Padmanabhan S et al. No beneficial effect of icodextrin on blood glucose control. Perit Dial Int 2004; 24: 199-200.
29. Gradden CW, Ahmad R, Bell GM. Peritoneal dialysis: new developments and new problems. Diabet Med 2001; 18: 360-363.
30. Segal KR, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996; 45: 988-991.
31. Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
32. Huang JW, Yen CJ, Chiang HW et al. Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. Am J Kidney Dis 2004; 43: 1047-1055.
33. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141.
34. Opatrná S, Opatrný K Jr, Racek J et al. Effect of Icodextrin-Based Dialysis Solution on Peritoneal Leptin Clearance. Perit Dial Int 2003; 23: 89-91.
35. Furuya R, Odamaki M, Kumagai H et al. Beneficial effects of icodextrin on plasma level of adipocytokines in pentoneal dialysis patients. Nephrol Dial Transplant 2006; 21: 494-498.
36. Tintillier M, Pochet JM, Christophe JL et al. Transient sterile chemical peritonitis with icodextrin: clinical presentation, prevalence, and literature review. Perit Dial Int 2002; 22: 534-537.
37. Martis L, Patel M, Giertych JBS et al. Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution. The Lancet 2005; 365: 588-594.
38. Davies SJ, Brown EA, Frandsen NE et al. Longitudinal membrane function in functionally anuric patients treated with APD: Data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 2005; 67: 1609-1615.
39. Kuriyama R, Tranaeus A, Idegami T. Icodextrin reduces mortality and the drop-out rate in Japanese peritoneal dialysis patients. Adv Perit Dial 2006; 22: 108-110.